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There are now numerous reports (1-5) showing that mAbs can be effective as 
therapeutic agents in a variety of diseases. A major complication encountered in 
many of these studies has been the antiglobulin response that such xenogeneic 
Igs elicit (6-10). This acts both to curtail the prospect of long-term therapy and 
to risk potentially harmful hypersensitivity reactions. Two strategies have been 
suggested that might be  used  to mitigate such  unwanted responses.  The first 
involves  induction  of tolerance  to  the  xenogeneic  mAb  before  commencing 
therapy. The second requires the use of either human mAbs or chimeric mAbs 
constructed by combining human constant gene  segments with mouse or  rat 
variable gene segments (1 !-13). Natural tolerance to human determinants would 
be  expected  to  reduce  the  immune  response  to  such  mAbs  when  used  as 
therapeutic agents in clinical practice. Both strategies have a common problem. 
Simply put, it is whether tolerance can ever be attained to the unique variable 
region (i.e., idiotype) of a  given therapeutic mAb, and if not, will tolerance to 
constant  region  epitopes  be  sufficient to  prevent  the  response  to  the  whole 
molecule? 
The concept of tolerance reducing an immune response to Igs is supported by 
a vast literature involving the induction of tolerance to polyclonal heterologous 
Igs in mice (14),  and there is some evidence that such tolerance may reduce the 
antiglobulin response to therapeutic polyclonal antilymphocyte globulins (ALG) 
(15,  16). Therapeutic  mAbs differ from polycional Ig in  two major features, 
which make it impossible to predict their behavior as tolerogens. First, they bind 
to specific antigens on cells or in solution. This would have a substantial influence 
on their uptake and presentation as immunogens. Second, they are monoclonal 
and  therefore  highly homogeneous.  Each  injection of mAb  would  contain  a 
relatively  high  immunogenic dose  of  the  idiotypic  determinants.  That  such 
homogeneity can affect immunogenicity is well demonstrated by classical exper- 
iments (17-19) that have shown that relatively pure antiallotype, antiidiotype, or 
antisubclass immune responses can be elicited in laboratory animals, by immu- 
nization of one strain with Igs of restricted heterogeneity (i.e., myeloma proteins 
or mAbs) from another, or by first rendering an animal tolerant to one Ig type 
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and then immunizing with another. Adjuvants have generally been used to elicit 
such responses.  Two implications can  be drawn  from these experiments.  First, 
tolerance to one part of an  Ig may not always prevent an immune response to 
the rest of that Ig. Second, contrived circumstances of antigen presentation (e.g., 
adjuvant)  may be necessary to elicit such responses.  In  contrast, recent studies 
(20)  involving  tolerance  to  hen  egg  lysozyme (HEL) have  shown  that  certain 
epitopes on a molecule may evoke suppressor mechanisms that render the animal 
tolerant to the whole molecule. There is no a priori reason why such a tolerance 
mechanism should not operate with respect to mAbs to prevent the antiglobulin 
response. 
In view of such conflicting data, it cannot be predicted whether tolerance, be 
it  natural  or acquired,  could  prevent antiglobulin  responses  to  mAbs  used  in 
therapy. In this study, we have addressed a number of questions that we feel are 
central  to  resolving  this  uncertainty.  (a)  Is  it  possible  to  induce  tolerance  to 
mAbs? (b) If it is possible, will the antigen binding potential of an mAb influence 
its ability to tolerize? (c) Will tolerance to the constant region of an mAb influence 
whether or not a response can be generated to idiotypic determinants? 
The results described here lead us to conclude that operational  tolerance to 
xenogeneic mAbs can be achieved in  mice by classical deaggregation methods, 
and also by the use of an anti-L3T4 mAb in a novel tolerance-inducing regimen. 
This is the case for mAbs that do not have specificity for cell surface antigens 
(non-cell-binding mAbs), however the situation for mAbs that bind to cell surface 
antigens (cell-binding mAbs) is different, as full tolerance is difficult to achieve. 
Indeed, even in the presence of tolerance to constant region determinants,  cell- 
binding  mAbs  still  elicit  strong  antiidiotypic  responses.  This suggests  that  the 
antiidiotypic response will remain a constraint on extended serotherapy directed 
towards  cellular  antigens,  even  with  the  use  of human  and  chimeric  mAbs. 
Further strategies must be developed to prevent this complication. 
Materials and Methods 
Mice.  CBA/Ca mice were bred and maintained at the animal facility of the Department 
of Pathology, University of Cambridge.  Male mice 6-8 wk old were used in groups of 
five in all experiments. 
Monodonal Antibodies.  Rat mAbs were produced by a modified protocol of Galfre and 
Milstein (21) by fusion of the rat myeloma Y3.Ag 1.2.3 (22) and DA rat spleen cells, mAbs 
were purified from ascitic fluids produced in  Pristane-(Aldrich T2  280-2;  Gillingham, 
United Kingdom) primed (DA ×  LOU)F~ rats. The Ig fraction was prepared by precipi- 
tation with 50% saturated ammonium sulfate, and then ion-exchange chromatography on 
a  DEAE-cellulose column (Whatman  DE-52;  Maidstone,  United  Kingdom) in  0.01  M 
sodium phosphate buffer, pH 8.0. The mAbs were then dialyzed into PBS,  the protein 
concentration was estimated by measuring the absorbance at 280 nm, and the mAbs were 
stored at -20°C  until  use.  The binding activity of each purified mAb was checked by 
immunoperoxidase staining on mouse spleen sections. None of the anti-human  mAbs 
crossreacted on  mouse  cells.  The  anti-mouse  lymphocyte antibodies  were  previously 
described by Cobbold et al. (23).  All the mAbs used were of the IgG2b subclass and are 
listed in Table I. 
Induction  of Classical Tolerance to YTH 3.2.6.  Mice were tolerized by i.p. injection of 
0.5 mg of deaggregated YTH 3.2.6 (Campath 2) (24) in  1 ml sterile PBS, according to 
the method of Dresser (25). Deaggregation was achieved by ultracentrifugation at 150,000 
g for 150 rain (L8-70M; Beckman Instruments, Palo Alto, CA) of 5 m] aliquots of mAb BENJAMIN  ET  AL.  1541 
TABLE  I 
mAbs Used 
mAbs*  Specificity 
YTS 154.7  Anti-Thy-  1 
YTS 169.4  Anti-Lyt-2 
YTS 121.1  Anti-Lyt-  1 
YTS 191.1  Anti-L3T4 
YBM 15.1.6  Anti-mouse neutrophil 
YTH 3.2.6 (Campath 2)  Anti-human CD 7 
YTH 12.5.14 (Campath 3)  Anti-human CD 3 
YTH 24.5  Anti-human T200 antigen 
YTH 65.3.33  Anti-human T200 antigen 
YTH 53.1.4  Anti-human RBC 
* All mAbs are of the rat IgG2b~ subclass except YTH 12.5.14,  which is 
IgG2bh. mAbs were previously described (23, 24, 27, 44), except YTH 
53.1.4, which is our unpublished data. 
at  I0 mg/ml.  After ultracentrifugation, the top one-third of each aliquot was carefully 
removed, the protein  concentration  was determined, and  after appropriate dilution in 
sterile saline, the mAb was injected into mice. This procedure was kept as short as possible 
to avoid reaggregation of the mAb. 
Induction of Tolerance  to Rat IgG2b Determinants by Anti-L3T4  Therapy.  As previously 
described (26), mice were rendered tolerant to rat IgG2b determinants by injections of 2 
mg (~0.4 mg active mAb) YTS 191.1  (anti-L3T4 antigen) on day 0  (i.v.), and on days 1 
and  2  (i.p.). This mAb was purified from  ascites by ammonium  sulfate precipitation as 
above, dialyzed against sterile saline, and then stored at -20°C until use. Controls received 
either an irrelevant IgG2b mAb (YTH 65.3.33 [27]) or saline by the same protocol. These 
mice  were  then  maintained  on  antibiotics (oxytetracycline 50  rag/liter)  (Terramycin; 
Pfizer, Sandwich, United Kingdom), and were free of any obvious disease. 
Immunization.  After classical tolerance induction to YTH 3.2.6, mice were immunized 
with 0.5 mg doses of the immunizing mAbs on day 9 (i.v.) and day 19 (i.p.), and bled on 
day 24.  After tolerance induction by anti-L3T4 therapy, mice were immunized on days 
42 (i.p.) and 52 (i.p.), and bled on day 58. The sera were separated and stored at -20°C 
until assay. The immunizing mAbs were used in their soluble form except where this gave 
inconsistent  immunization  in  normal  mice.  For  this  reason,  YBM  15.1.6,  YTH 3.2.6, 
YTH 53.1.4, and YTH  12.5 were partially aggregated to increase their immunogenicity 
by heating the purified mAb at  10 mg/ml for 25 min at 63°C followed by placing on ice 
overnight, in  a  modification of the  protocol of Weigle (14).  This partially aggregated 
preparation was then stored at -20 °C until use. 
Measurement of Serum Antibodies  to Rat IgG.  Anti-rat IgG antibody titers were assessed 
by a  solid-phase EL|SA. Microtitration trays were coated with the immunizing mAb by 
incubation of 50 gl/well of a 20 gg/ml solution in PBS for 60 min, and were then washed 
three times in 0.05%  (vol/vol) Tween  20 (Sigma Chemical Co., Poole, United Kingdom) 
in  PBS.  Trays were then  blocked overnight with a  1%  (wt/vol) solution of BSA (Sigma 
Chemical Co.) in PBS plus 0.02%  (wt/vol) sodium azide. The trays were washed before 
use and between each step in the assay as above. Test serum samples were added to the 
trays at 50 ul/well, serially diluted in 0.1%  (wt/vol) BSA/PBS, and were then incubated 
for  60  rain  at  20°C,  followed sequentially by  biotinylated species-specific sheep  anti- 
mouse Ig (Amersham Corp., Amersham,  United Kingdom) and strepavidin-horseradish 
peroxidase complex (Amersham Corp.) each diluted 1:1,000 and incubated for 35 rain at 
room temperature. Bound enzyme was then detected by the addition of the substrate 0- 
phenylenediamine, incubated at 100 #l/well for 5 min, and the reaction stopped by adding 
3  M  H2SO4 (30 ul/well). Absorbance was read at  490  nm,  and  values for each sample 
were plotted graphically against the dilution. The titer was then read relative to a standard 
positive control consisting of a mixture of 1:10 ascites of the following mouse anti-rat Ig 1542  TOLERANCE  TO  RAT  MONOCLONAL  ANTIBODIES 
mAbs: NORIG 1.1.6, NORIG 7.16.2 (both anti-rat IgG2b) (28, 44) and MAR 18.5 (anti- 
rat K  light chain) (29).  Normal mouse serum was used as a negative control and consistently 
gave titers of <1:5. 
Detection of Serum Antiidiotype  Antibodies.  Antibodies to rat mAb idiotypes were de- 
tected  indirectly  by comparing the  relative titers  of a  given  anti-serum  to  either  the 
immunizing  mAb  or  two  irrelevant  rat  IgG2b  mAbs,  as  determined  by  the  ELISA 
technique above (9,  10). 
Measurement of Rat IgG2b in Mouse Serum.  Circulating fi-ee rat IgG2b in mouse serum 
was detected by an ELISA. Microtitration trays were coated with NOR1G 7.16.2 (mouse 
anti-rat IgG2b), blocked overnight, and serial dilutions of sermn samples were applied 
and incubated as above. Bound IgG2b was then detected by biotinylated NORIG 1.1.6 
(mouse anti-rat IgG2b) at 2 ug/ml. This was followed by strepavidin-horseradish perox- 
idase complex (Amersham Corp.) and the substrate 0-phenylenediamine, as above. Positive 
controls were constructed by adding known amounts of YTH 3.2.6 to normal CBA/Ca 
mouse serum, and a standard curve was generated from which test concentrations were 
determined. 
Preparation of H2L2 and HzKz variants of YTS 169.4.  The myeloma line Y3 Ag 1.2.3, 
used to produce all the above rat mAbs, secretes an Ig light chain of the LOU rat g la 
allotype (22).  After fusion with a DA rat spleen cell to produce a hybridoma cell,  the Ig 
chains from both parental cells are codominantly expressed (30), and the individual chains 
can associate randomly to form a complex mixture of molecules. The association of the 
spleen cell-derived H  chain with the spleen cell-derived L chain (g  lb or X) usually has 
antigen  specificity, while its association  with the myeloma-derived light chain (K)  ~ does 
not (3 I). The hybridomas thus produce a  mixture of bivalent nonspecific (H=K2), mon- 
ovalent (H~LK), and bivalent specific (H~L2) mAbs. The H2K2 and H2L2 forms of YTS 
169.4 were purified from serum-free culture supernatants dialyzed into 20 mM Tris HCI 
(Sigma Chemical  Co.),  pH  7.5,  and  then  subjected  to  HPLC  (Ultra  Pac  column  TSK 
DEAE 5PW;  LKB-Produckter, Bromma, Sweden).  The first three peaks eluted off this 
column by a  0-400  mmol NaCI gradient were shown to contain the  H2L2, H2LK, and 
H2K2 forms,  respectively,  by  an  inhibition  of passive  hemagglutination  assay,  which 
detected the relative amounts of the heavy chain isotype and light chain allotypes in each 
peak (32). 
Results 
Induction of Tolerance to Rat mAb by Classical Methods.  Tolerance to polyclonal 
IgG  can  classically  be  induced  in  mice  by  i.p.  injection  of  the  IgG  in  the 
deaggregated form (25). Such tolerance has been shown (14) to be fully developed 
within 5 d of injection, to last up to  120 d and to be specific for the injected IgG. 
In our initial experiments, we showed that, in an analogous fashion, mice can be 
rendered tolerant to a  rat IgG2b mAb. We found  that mice pretreated with an 
i.p.  injection  of 0.5  mg of deaggregated  YTH  3.2.6  (anti-human  CD  7),  and 
then  immunized  9  d  later  with  the  immunogenic  heat-aggregated  form  of the 
same mAb, produced 95-98% less antiglobulin response after 15 d than controls 
that  had  not  been  so  pretreated.  This  result  was  highly  reproducible,  and  is 
exemplified in  a  control  group in  Fig.  1 (immunizing  mAb YTH  3.2.6).  Later 
bleeds confirmed that there had been no delayed immune response.  Unrespon- 
siveness persisted  for at  least  31  d  after  injection  of deaggregated  material.  It 
was not  possible to induce  tolerance by this method  to a  number of mAbs with 
binding specificity  for mouse cell  surface antigens  (cell-binding  mAb),  as even 
after deaggregation, these elicited strong antiglobulin responses (data not shown). 
One  criticism  of  using  serological  assays  such  as  the  ELISA  to  measure 
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FIGURE  i.  The antiglobulin  response of mice tolerant  to YTH 3.2.6 after immunization 
with various different  IgG2b mAbs. Mice were rendered YTH 3.2.6 unresponsive (open bars) 
by i.p. injection of 0.5 mg deaggregated  YTH 3.2.6 on day 0. Controls (filled bars) received 
saline. Randomly selected mice were then immunized on days 9 (i.v.) and 19 (i.p.) with 0.5 mg 
of one of the immunizing mAbs shown, then  bled on day 24. Antiglobulin responses were 
measured by ELISA, and the geometric means and SDs of the antibody titers from five mice 
per group are shown. 
tolerance  has  been  the  potential  for  artifactual  inhibition  of the  titer  by  free 
serum tolerogen (14).  We excluded this possibility by directly measuring tolero- 
gen  in  serum  with a  sandwich  ELISA (see  Materials  and  Methods),  which  was 
sensitive enough  to detect  250  ng/ml  rat  IgG2b mAb in mouse serum, and  yet 
was  unable  to  detect  any  YTH  3.2.6  in  any  of the  sera  at  the  time  of assay. 
Furthermore,  in an  inhibition  assay where immune sera were preincubated  for 
2  h  after artificial addition  of free  YTH  3.2.6  mAb and  the  antiglobulin  titer 
then assayed, it was found  that  ~50  ug/ml free mAb was needed  to cause 50% 
inhibition  of the  measured titer (data not shown).  From this we concluded  that 
the titers as measured by the ELISA technique are a true reflection of tolerance. 
Antiglobulin Response of  Mice Tolerant to One IgG2b mAb on Challenge with Other 
IgG2b  mAbs.  Mice  rendered  tolerant  to  YTH  3.2.6  must necessarily  be unre- 
sponsive to the rat IgG2b determinants on the constant region of this mAb. As 
shown in Fig.  1, we determined how this tolerance would affect the ability of the 
immune  system to  mount  an  immune response  to  various other  IgG2b mAbs. 
Mice were rendered  tolerant to YTH  3.2.6  by pretreatment with deaggregated 
mAb on  day 0,  and  together  with  unpretreated  controls,  were immunized  9  d 
later with one of either four cell-binding mAbs or three non-cell-binding mAbs. 
Fig.  1 shows that control mice all made strong antiglobulin responses, confirming 
the immunogenicity of the  IgG2b subclass in mice. Mice tolerant of YTH  3.2.6 
responded  in  one of two ways.  They failed  to  respond  to any of the  non-cell- 
binding  mAbs  but  responded  vigorously  to  the  cell-binding  ones.  This  result 
implies that  tolerance  to  shared  constant  region  determinants  was sufficient to 
prevent  the  immune  response  to  the  whole  mo]ecule  in  the  case  of non-cell- 
binding mAbs, but was insufficient in the case of cell-binding mAbs. 
Characterization  of  Immune Response to Cell-binding mAbs.  The strong immune 
responses to cell-binding  mAbs in  tolerant mice in  Fig.  1 raised the question  of 
whether these mAbs actually overcame the unresponsiveness to constant region 
determinants,  or whether the responses measured were restricted to the unique 
variable  region  (i.e.,  the  idiotype)  of  the  mAbs.  To  detect  any  antiidiotypic 
component,  the  sera assayed in  Fig.  1  were  further  analyzed in  an  ELISA for 1544  TOLERANCE  TO  RAT  MONOCLONAL  ANTIBODIES 
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FIGURE 2,  Characterization of the antiglobulin responses to cell-binding mAbs in control 
and YTH 3.2.6 tolerant mice. The antiglobulin responses to cell-binding mAbs in control and 
YTH 3.2.6 tolerant mice from Fig. 1 were further analyzed by assaying the reactivity of the 
sera to the immunizing mAb (filled bars) and also to two of the following different IgG2b 
mAbs: YTS 169.4 H2L~ (striped bars); YTH 3.2.6 (open bars); or YTS 169,4 H2K2 (cross- 
hatched bars). Figure shows the geometric means and SDs of the antiglobulin titers from five 
mice per group. 
their reactivity to either the immunizing mAb or to irrelevant IgG2b mAbs.  In 
this way the antiidiotypic component would manifest as a preferentially high titer 
to the immunizing mAb as compared to the irrelevant IgG2b mAbs. Fig. 2 shows 
that  the  response  in  normal  mice  to  YTS  169.4  and  YTS  121.1  both  have a 
significant component directed against their idiotype, whereas this is not obvious 
with YTS  154.7 and YBM  15.1.6. Tolerant mice, in contrast, make a  response 
to all four cell-binding mAbs that is predominantly antiidiotypic. A closer analysis 
of the response to YTS  169.4 showed it to be directed mainly to the H2Lz and 
not the H2K2 form of this mAb. All the mAbs used to immunize were mixtures 
of the bivalent specific (H2L2), monovalent specific (HzLK), and bivalent nonspe- 
cific (H2K2) forms (see Materials and Methods). The antiidiotypic response could 
therefore apparently discern  the idiotype actually involved in cell binding (i.e., 
the HL idiotype). These results imply that the ability of an mAb to bind to cells 
renders the idiotypic determinants associated with cell binding major antigenic 
stimuli, even in the presence of constant region tolerance. 
Therapy  with  mAb  YTS  191.1  Renders  Mice  Tolerant  to  Rat  IgG2b  Determi- 
nants.  The  rat  mAbs  YTS  191.1  (23) and  GK  1.5  (33),  directed against  the 
L3T4 antigen found on T  helper cells (34), are highly immunosuppressive when 
injected in vivo, and are unique as examples of IgG2b mAbs, as they do not elicit 
antiglobulin responses to themselves (1, 3,  23,  35,  36). We have recently shown 
(26) that mice treated with YTS 191.1 regain full immunocompetence within 42 
d  of therapy,  but remain  specifically tolerant to rat  IgG2b determinants.  This 
tolerance was demonstrated by the failure of treated mice to make an immune 
response to two non-cell-binding mAbs, at a time point when they were capable 
of a  normal  response  both  to  heat-aggregated  human  3,  globulin  (HGG) and 
chicken y  globulin (CGG). Furthermore mice injected with aggregated HGG at 
the  time of anti-L3T4  therapy not  only failed to respond  to this antigen,  but 
were also found to be specifically unresponsive (i.e., tolerant) on later rechallenge 
with the same antigen.  These findings raise a  number of questions with respect 
to the present study. First, how would tolerance to IgG2b determinants induced 
by anti-L3T4 therapy affect the immunogenicity of cell-binding mAbs? Second, 
would anti-L3T4 therapy given concomitantly with cell-binding mAbs  prevent BENJAMIN  ET  AL.  1545 
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FIGURE 3.  Antiglobulin responses in mice rendered rat lgG2b-tolerant by treatment with 
anti-L3T4 mAb. Mice were rendered IgG2b-tolerant  by injections of 2 mg of YTS  191.1 
(anti-L3T4 mAb) on days 1 (i.v.) or 2 and 3 (i.p.), or received an irrelevant IgG2b mAb (lrret. 
mAb) (YTH 65.3.33)  or saline by the  same protocol.  Randomly selected mice were  then 
immunized i.p. on days 42 and 52 with either YTH 3.2.6 (non-cell-binding), YTS 154.7 (anti- 
Thy-1) or YTS 169.4 (anti-Lyt-2). Mice were bled on day 58, and the antiglobulin responses 
of each serum were determined on plates coated with either YTH 3.2.6 (open bars), YTS 
154.7 (striped bars), or YTS 169.4 (filled bars) by ELISA. Figure shows the geometric means 
and SDs of the antiglobulin titers of five mice per group. 
the antiglobulin response to these, and if so, would the mice be tolerant on later 
rechallenge with the same cell-binding mAbs? 
Cell-binding IgG2b  mAbs Elicit Antiidiotypic Responses in Mice Rendered  IgG2b 
Tolerant by Anti-L3T4 Therapy.  In Fig.  3, mice were rendered  IgG2b tolerant, 
as previously described (26),  by pretreatment  with injections of 2  mg (~0.4  mg 
active  mAb)  of YTS  191.1  on  day  0  (i.v.),  and  days  1  and  2  (i.p.).  Controls 
received  an  irrelevant  mAb or  saline.  They were  then  immunized  on  days 42 
and  52 (i.p.) with  either YTS  169.4  (anti-Lyt-2) or YTS  154.7  (anti-Thy-1),  or 
as a  control with YTH  3.2.6 (non-cell-binding),  and bled on day 58. The figure 
shows that anti-L3T4-pretreated  mice failed to mount an antiglobulin  response 
to  YTH  3.2.6,  which  confirms  that  this  pretreatment  renders  mice  IgG2b 
unresponsive.  The  two  cell-binding  mAbs,  on  the  other  hand,  both  elicited 
predominantly antiidiotypic  responses in pretreated mice, confirming our find- 
ings above that  cell binding  renders  the  idiotype of an  mAb a  major antigenic 
determinant even in the presence of constant region tolerance. 
Anti-L3T4  Therapy  Does Not  Induce  Tolerance  to  Idiotype of  Cell-binding 
mAbs.  We  next  asked  whether  the  same  anti-L3T4  protocol  that  we  have 
previously  shown  is  able  both  to  ablate  the  normal  immune  response  and  to 
render mice tolerant to heat-aggregated HGG would have the same effect on rat 
IgG2b  mAbs.  In  Fig.  4,  mice  were  pretreated  with  YTS  191.1,  an  irrelevant 
mAb, or  saline  on  days 0,  1,  and  2  as before, and  were then  injected  (i.p.) on 
days  2  and  3  with  0.5  mg of either  YTS  169.4  (anti-Lyt-2);  YTS  154.7  (anti- 
Thy-1);  YTH  3.2.6  or  YTH  53.1.4  (both  non-cell-binding).  These  mice were 
then bled on days  ] 2 and 42, and their antiglobulin  titers were measured by an 
ELISA. Fig.  4  shows that by day  12,  anti-L3T4-treated  mice failed to respond 
to  any  of the  injected  mAbs,  while  controls  produced  strong  responses.  This 
confirms a  recent abstract report (37) that antiglobulin responses can be ablated 
by concommitant anti-L3T4  therapy.  However, a  late bleed on day 42 showed 
that,  while  the  antiglobulin  responses  in  control  mice  had  begun  to  fall,  mice 1546  TOLERANCE  TO  RAT  MONOCLONAL  ANTIBODIES 
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that  had  received  anti-L3T4  pretreatment  had  made a  late  response  to the  two 
cell-binding  mAbs,  but  not to the  non-cell-binding  ones.  These  mice were then 
rechallenged  on days 42 and  52 wih the same mAbs as had been  injected  on days 
2  and  3,  and  were  again  bled  on  day  58.  Fig.  5  shows  that  the  anti-L3T4- 
pretreated  mice  injected  with  the  two  non-cell-binding  mAbs  (YTH  3.2.6  and 
YTH  53.1.4)  failed  to respond  to late rechallenge,  while those  injected  with  the 
cell-binding  mAbs  (YTS  169.4  or  YTS  154.7)  produced  strong  antiidiotype 
responses.  We therefore conclude  that with this anti-L3T4  protocol  it is possible 
to  induce  tolerance  to  rat  IgG2b  constant  region  determinants,  but  not  to  the 
idiotypic  determinants  of cell-binding  mAbs.  We  have  recently  been  informed 
of  the  basically  similar  results  of  Gutstein,  Wofsy,  and  Seaman  (personal  com- 
munication),  who  note  that  anti-L3T4-pretreated  mice given  a  rat  IgG2b  mAb 
anti-mouse  T200  also produce  a  predominantly  antiidiotype  response. BENJAMIN ET  AL.  1547 
Discussion 
In this study we  have investigated whether tolerance may prevent the anti- 
globulin response to mAb when used as therapeutic agents. We report that, in 
mice, it  is  possible  to induce tolerance to rat  IgG2b mAbs both by means of 
classical deaggregation methods and by the newly described (26) method of anti- 
L3T4 therapy, but that the ability of an mAb to bind to a cell surface antigen 
limits induction by either method.  Furthermore, mice that are tolerant to rat 
IgG2b constant  region  determinants fail  to  respond  when  challenged with a 
short immunizing course of other non-cell-binding mAbs of the same subclass, 
regardless of whether these mAbs are heat aggregated or not, but produce rapid, 
predominantly antiidiotypic responses on immunization with cell-binding ones. 
Two other interesting observations arise from these results. First, the doses of 
cell-binding mAbs used to immunize mice were sufficient to cause >85% periph- 
eral depletion of their target cell subsets (23),  and yet none of the four mAbs 
tested were able to break completely the unresponsive state to constant region 
determinants, even though they elicited antiidiotypic responses. This may imply 
that  none  of Lyt-1  ÷,  Lyt-2  +,  Thy-1 + T  cells  nor  neutrophils  are  exclusively 
responsible for maintaining this  unresponsiveness by some suppressor  mecha- 
nism. Second, in the case of the antiidiotype response to YTS 169.4, the reactivity 
was to the HL (specific)  not the HK (nonspecific) idiotype. As both the H2L2 and 
monovalent  H2LK  forms  would  be  expected  to  bind  to  cells  and  to  cause 
depletion (38),  one  might have  expected a  response  to  both sets  of idiotypic 
determinants. It is possible that the greater avidity of the HzL2 competed out 
the binding of the H2LK form and so prevented it from becoming cell-bound 
and  therefore immunogenic.  It  will  be  interesting to  determine whether  the 
purified monovalent (H2LK) form elicits a response to both idiotypes in tolerant 
mice. 
The strong antiidiotypic responses to cell-binding mAbs in tolerant mice imply 
that  binding  of a  mAb  to  a  cell  surface  antigen  leads  to  effective  uptake, 
processing, and  presentation  of its  idiotypic determinants. Cell-binding could 
theoretically enhance this process in a  number of ways, for example, it would 
cause aggregation of the mAb on the cell surface; it would increase its immuno- 
genic half-life; it could, especially in the case of rat IgG2b mAbs, lead to rapid 
cellular  destruction  by  either  complement  activation  or  antibody-dependent 
cellular cytotoxicity (23, 39), with subsequent uptake and processing of the mAb 
bound to cellular debris; and finally, binding of an mAb to a cell surface receptor 
may  directly  modulate  cellular  functions.  All  these  factors  may,  in  certain 
circumstances, serve  to enhance immunogenicity. Whatever the exact  mecha- 
nism, we believe that the antiidiotypic response to cell-bound antibodies may be 
of great significance physiologically. We have found that an injection of as little 
as 1 #g of YTS 169.4 is able to provoke an antiidiotype response in tolerant mice 
(data not shown). We propose that, at this concentration, the immune system, 
which is tolerant to constant region epitopes, would see a cell-bound mAb in the 
same way as  it would see an autoantibody. The antiidiotypic response,  which 
could  be  both  humoral and/or cellular  in  nature,  may then  be  a  predictable 
reaction to any autoantibody directed to cell surfaces, in this way serving as a 
natural regulatory mechanism to limit autoimmunity. 1548  TOLERANCE  TO  RAT  MONOCLONAL  ANTIBODIES 
Another problem raised is how T  and B cells interact to give a relatively pure 
immune  response  to  the  idiotypic determinants  of an  mAb in  the  presence  of 
constant region tolerance.  If we were to consider idiotypes in this context to be 
analogous  to  haptens  on  a  carrier  molecule,  then  we  would  expect  carrier 
tolerance  to  prevent  a  response  to  the  hapten  (40).  However,  idiotypes  are 
composed of many different idiotopes duplicated  on each  Fab arm.  Therefore 
we could imagine  idiotope  1 (plus MHC) providing help for B cell response to 
idiotope  2.  Alternatively,  the  classical  dogma  applicable  to  haptens  may  not 
strictly apply here, and like-like help cannot be excluded. 
The  findings  of  this  study  with  regard  to  the  immunogenic  behavior  of 
therapeutic mAbs in the presence of constant region tolerance are important,  as 
they  may  predict  the  nature  of the  antiglobulin  responses  that  human  and 
chimeric mAbs might elicit in clinical practice. That tolerance to constant region 
determinants  is able to prevent an antiglobulin  response to a short immunizing 
course of non-cell-binding  mAbs,  either  soluble or aggregated,  would predict 
that human and chimeric mAbs to soluble antigens (e.g., to digoxin [41] or snake 
venom  factors)  would  fail  to  elicit an  antiglobulin  response  even  though  they 
would be functionally aggregated in vivo by forming immune complexes. From 
the point of view of clinical therapy, the antiidiotype response that cell-binding 
mAbs elicit in the presence of constant region tolerance is much more ominous, 
as such a  response  to human  and chimeric  mAbs would negate their proposed 
advantages.  Our work therefore calls into doubt the suggestion that human  or 
chimeric mAbs will be the panacea for all antiglobulin  responses, and raises the 
question  whether  the  antiidiotype  response  to  cell-binding  mAbs  can  be  pre- 
vented.  Cytotoxic drugs  and  steroids  are  the  most  readily  available  means  of 
nonspecifically suppressing  unwanted immune responses, and have been shown 
to be effective in limited clinical trials with therapeutic mAbs (42), but this form 
of therapy exposes the patient to the dangers of generalized immunosuppression 
and also mitigates  the highly selective therapeutic  potential  of mAbs.  Another 
strategy stems from the previous observation that anti-mouse globulin responses 
in  clinical  trials  often  have  a  significant  antiidiotypic  component  (10).  These 
authors suggest the sequential use of a number of mAbs against the same antigen 
but  with  different  idiotypes,  to  avoid  the  complications  of the  antiglobulin 
response  without preventing  its occurrence.  Our  data support this  suggestion, 
the  only  proviso  being  that  the  mAbs  be  of an  isotype  suitable  to  ensure 
therapeutic effectiveness in vivo (23,  39, 43, 44). Another possibility is the use 
ofanti-L3T4 (CD 4) mAb therapy. In this paper we have shown that such therapy 
is able to  induce  tolerance  to  the  constant  region  determinants  on  rat  IgG2b 
mAbs and prevent the early antiidiotypic response to cell-binding mAbs. It may 
be  that  with  more  aggressive  anti-L3T4  therapeutic  protocols,  the  complete 
abolition of the antiidiotype  response,  or even tolerance,  to cell-binding mAbs 
would be possible. We are presently investigating this possibility, mindful of the 
obvious disadvantage that such a protocol would expose the patient to the dangers 
of a potently immunosuppressive regimen. 
An alternative way of looking at the antiidiotype problem is to determine why 
rat IgG2b mAbs, which are highly effective at depleting their target T  cell subsets 
in  vivo, do not also bind specifically to and deplete B cells that carry Ig surface BENJAMIN ET  AL.  1549 
receptors  directed against their  idiotype (i.e.,  antiidiotypic B  cells),  and  so by 
clonal deletion prevent the antiidiotype response. It may be that such B cells are 
in privileged sites within the immune system, and avoid destruction, or it may 
be  that  many  are  destroyed  but  a  small  number  escape  to  give  rise  to  the 
antiidiotypic response. It is a likely possibility that an mAb binding to antiidiotypic 
B cells would cause the Ig receptors of these cells to be rapidly modulated and 
internalized (46). This would protect the B cell from destruction and may even 
constitute a triggering signal. If this were the case, then it should be possible to 
find ways to clonally delete antiidiotypic B cells, say by preventing such modu- 
lation  using monovalent mAbs  (38),  or  by  using toxin-linked  mAbs  (45)  that 
could kill the antiidiotypic B cells after internalization. 
In  conclusion,  the  antiglobulin  response  is  a  major  complication  of mAb 
therapy that cannot as yet be predictably avoided in clinical practice by the use 
of human or chimeric mAbs. 
Summary 
The antiglobulin response is a major complication of mAb therapy. It has been 
suggested  that,  in  clinical practice,  this  might be  avoided by  using human  or 
chimeric mAbs, or by prior induction of tolerance to the therapeutic mAb.  In 
this study, we show that it is possible to induce tolerance in mice to the constant 
regions of rat IgG2b mAbs by both classical deaggregation methods and by anti- 
L3T4 mAb therapy. Mice tolerant to IgG2b constant region determinants failed 
to make an antiglobulin response when immunized with a  number of mAbs of 
the same isotype that had no binding specificity for mouse cells, but produced 
vigorous antiidiotypic responses to cell-binding mAbs.  Binding of antibodies to 
hemopoietic cells rends their idiotypic determinants major immunogens even in 
the presence  of tolerance  to constant region  epitopes.  These  findings suggest 
that the use of human or chimeric mAbs will not be sufficient to eliminate the 
antiglobulin response, and that additional methods need to be investigated. 
Received for publication  12 February  1986. 
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